Oesophageal squamous cell carcinoma

7 trials 3 recruiting MedDRA PT
7 Registered trials
3 Recruiting
7 Unique sponsors
3 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Kinase inhibitor 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Phase III: 1 Phase I: 4 Phase I (Other): 1 Phase I (First in Human): 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

1 trial

Phase I

4 trials
  • Beigene Ltd. Commercial
    IMP not specified
    2023-505322-34-00 1 country 2024 n=45
    Ended
  • BeOne Medicines AG Commercial
    IMP not specified
    2023-506888-34-00 1 country 2024 n=91
    Recruiting
  • Seagen Inc. Commercial
    IMP not specified
    2023-506604-18-00 6 countries 2024 n=177
    Recruiting
  • Novartis Pharma AG Academic
    IMP not specified
    2022-500540-38-00 5 countries 2023 n=88
    Ended

Phase I (Other)

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-506227-29-00 2 countries 2024 n=60
    Recruiting

Phase I (First in Human)

1 trial
  • Salubris Biotherapeutics Inc. Commercial
    JK08; LENVATINIB; PEMBROLIZUMAB
    2024-511750-53-00 2 countries 2022 n=130
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Beigene Ltd. Commercial 1 Phase I 0
BeOne Medicines AG Commercial 1 Phase I 1
Seagen Inc. Commercial 1 Phase I 1
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I (Other) 1
Salubris Biotherapeutics Inc. Commercial 1 Phase I (First in Human) 0
Novartis Pharma AG Academic 1 Phase I 0
Unicancer Academic 1 Phase III 0
New trials by year
2022
2
2023
1
2024
4
← All indication landscapes